Inhibikase Therapeutics Income Statement (2020-2026) | IKT

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
1.36M0.33M0.00M0.05M0.01M0.01M0.06M0.06M0.12M0.08M1.00
Operating items
Research & Development (Quarter)
2.38M3.15M3.39M3.02M2.98M2.98M3.05M2.85M4.54M3.23M13.59M2.75M3.08M4.19M7.19M10.51M5.27M0.06M6.36M0.43M
Selling, General & Administrative (Quarter)
1.61M1.64M1.65M1.67M1.66M1.54M1.34M1.93M1.78M1.62M1.40M2.03M1.97M1.64M5.74M5.25M5.92M5.61M6.77M7.38M
Other Operating Expenses (Quarter)
-10.59M-1.16M-0.36M7.10M0.64M10.03M
Operating Expenses (Quarter)
3.99M4.80M5.04M4.69M4.65M4.52M4.40M4.78M6.32M4.85M4.40M4.78M5.05M5.83M12.93M14.60M10.83M12.77M13.78M17.84M
Operating Income (Quarter)
-2.63M-4.47M-5.04M-4.64M-4.64M-4.51M-4.33M-4.71M-6.20M-4.77M-4.40M-4.78M-5.05M-5.83M-12.93M-14.60M-10.83M-12.77M-13.78M-17.84M
EBIT (Quarter)
-2.63M-4.47M-5.04M-4.64M-4.64M-4.51M-4.33M-4.71M-6.20M-4.77M-4.40M-4.78M-5.05M-5.83M-12.93M-14.60M-10.83M-12.77M-13.78M-17.84M
Non-operating items
Non Operating Investment Income (Quarter)
0.03M-0.17M0.00M-0.00M776.000.00M-0.04M0.04M-0.00M-0.00M0.03M-0.05M
Interest & Investment Income (Quarter)
0.02M
Net income details
EBT (Quarter)
-2.64M-4.47M-5.02M-4.64M-4.64M-4.56M-4.33M-4.76M-6.24M-4.80M-4.40M-4.80M-5.24M-5.98M-12.93M-14.60M-10.87M-12.77M-21.48M-17.84M
Profit After Tax (Quarter)
-2.64M-4.47M-5.04M-4.64M-4.64M-4.49M-4.28M-4.48M-5.78M-4.60M-4.18M-4.65M-4.96M-5.78M-12.13M-13.68M-9.92M-11.93M-12.73M-16.38M
Income from Continuing Operations (Quarter)
-2.64M-4.47M-5.02M-4.64M-4.64M-4.56M-4.33M-4.76M-6.24M-4.80M-4.40M-4.80M-5.24M-5.98M-12.93M-14.60M-10.87M-12.77M-21.48M-17.84M
Consolidated Net Income (Quarter)
-2.64M-4.47M-5.02M-4.64M-4.64M-4.56M-4.33M-4.76M-6.24M-4.80M-4.40M-4.80M-5.24M-5.98M-12.93M-14.60M-10.87M-12.77M-21.48M-17.84M
Income towards Parent Company (Quarter)
-2.64M-4.47M-5.02M-4.64M-4.64M-4.56M-4.33M-4.76M-6.24M-4.80M-4.40M-4.80M-5.24M-5.98M-12.93M-14.60M-10.87M-12.77M-21.48M-17.84M
Net Income towards Common Stockholders (Quarter)
-2.64M-4.47M-5.02M-4.64M-4.64M-4.56M-4.33M-4.76M-6.24M-4.80M-4.40M-4.80M-5.24M-5.98M-12.93M-14.60M-10.87M-12.77M-21.48M-17.84M
Additional items
EPS (Basic) (Quarter)
-1.29-1.07-1.66-1.10-1.10-1.09-1.03-1.04-1.19-0.90-0.83-0.76-0.70-0.67-0.55-0.16-0.12-0.14-0.22-0.10
EPS (Diluted) (Quarter)
-1.29-1.07-1.66-1.10-1.10-1.09-1.03-1.04-1.19-0.90-0.83-0.76-0.70-0.67-0.55-0.16-0.12-0.14-0.22-0.10
Shares Outstanding (Quarter)
2.04M4.19M3.03M4.20M4.20M4.20M4.20M4.59M5.23M5.34M5.33M6.34M7.54M8.88M23.71M89.54M90.01M90.05M98.31M172.31M
Shares Outstanding (Diluted) (Quarter)
2.04M4.19M3.03M4.20M4.20M4.20M4.20M4.59M5.23M5.34M5.33M6.34M7.54M8.88M23.71M89.54M90.01M90.05M98.31M172.31M
Shares Outstanding (Entity) (Quarter)
2.04M4.19M3.03M4.20M4.20M4.20M4.20M5.18M5.29M5.36M6.19M6.48M7.22M7.46M23.71M
EBITDA (Quarter)
-2.63M-4.47M-5.04M-4.64M-4.64M-4.51M-4.33M-4.71M-6.20M-4.77M-4.40M-4.78M-5.05M-5.83M-12.93M-14.60M-10.83M-12.77M-13.78M-17.84M
Interest Expenses (Quarter)
0.01M157.00-0.02M973.000.07M0.05M0.04M0.03M0.02M0.19M0.15M0.00M0.04M7.70M